LQDA
Liquidia Corporation
$68.62
-3.42%
2026-08-21
About Liquidia Corporation
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
Key Fundamentals
P/E Ratio
53.17
Forward P/E
13.18
EPS (TTM)
$1.40
ROE
131.8%
Revenue Growth (YoY)
1842.7%
Profit Margin
30.7%
Debt/Equity
93.74
Price/Book
60.52
Beta
0.57
Market Cap
$6.66B
Avg Volume (10D)
1.9M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$93.61
60D Low
$53.06
Avg Volume
1.9M
Latest Close
$68.62
Get breakout alerts for LQDA
Sign up for Breakout Scanner to receive daily notifications when LQDA triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Liquidia Corporation (LQDA) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors LQDA daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. LQDA operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.